查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371877

到 2030 年血液疾病市場預測：按類型、疾病、治療類型、配銷通路和地區進行的全球分析

Blood Disorders Market Forecasts to 2030 - Global Analysis By Type (Hemophilia A, Hemophilia B, Von Willebrand Disease and Other Types), Disorder, Treatment Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球血液疾病市場規模為 150.8 億美元，預計到 2030 年將達到 267.3 億美元，預測期內年複合成長率為 8.6%。

血液疾病是一組影響血液及其成分的疾病。血液疾病也稱為血液疾病或血液疾病。有些血液疾病從出生起就具有遺傳性，而有些血液疾病則是由於多種要素導致的，包括感染疾病、自體免疫疾病和接觸某些毒素。治療選擇包括藥物和生活方式的改變以及更強化的治療。

根據世界血友病聯合會的報告，2017 年全球約有 315,423 人受到血液疾病的影響。其中，196,706 人患有血友病，76,144 人患有馮維勒布蘭氏症 (VWD)，42,573 人患有其他血液疾病。

臨床試驗和研發增加

對臨床試驗和研究與開發的日益重視導致血液疾病的診斷和管理顯著改善。更準確、更靈敏的血液疾病診斷測試的開發是研究和開發的結果。這些測試可以更快、更準確地鑒定，使醫療保健相關人員能夠更早開始治療患者。血液疾病臨床試驗、研發投資的增加以及患者預後的顯著改善正在推動市場擴張。

缺乏標準化指導方針

血液疾病的複雜性和多樣性、某些亞型研究的缺乏以及對個體化治療策略的需求導致缺乏標準化建議。血液疾病的治療通常需要血液學家、腫瘤學家、遺傳學家和其他醫療保健專業人員之間的合作。這些不同專業人員之間的護理協調可能會導致治療策略的改變。同時，資源限制和罕見疾病資料缺乏阻礙了市場擴張。

人們對血液疾病的認知不斷提高

作為改善醫療保健系統和解決全球健康差距的更大措施的一部分，增加開發中國家對血液疾病的了解將改善這些疾病患者的健康和福祉，這是重要的一步。認知的提升為研究血液疾病和尋找治療方法配合措施了更多的資金和關注。結果，用於研究和開發的資金不斷增加，意識提升配合措施不斷增加，市場需求不斷增加。

報銷政策不完善

血液疾病的治療包括成本高昂的最先進治療，如基因治療和幹細胞移植。血液疾病的治療通常涉及多學科方法，其中包括血液學家、腫瘤學家、遺傳學家和其他專家的意見。此外，市場規模有限、治療計劃複雜以及缺乏競爭等要素可能會限制政府和競爭性保險公司的預算並降低報銷率。這些問題都阻礙了市場需求。

COVID-19 的影響

COVID-19 的疫情對血液疾病市場產生了重大影響。大流行導致常規醫生預約和診斷測試的延誤，導致血液疾病的診斷和治療的延誤。這場大流行擾亂了全球藥品和醫療設備供應鏈，導致血液疾病基本藥物的分配延遲和短缺。

預計預測期內血癌領域規模最大

血癌領域預計將出現良好的成長。血癌發生在人體的造血組織中，例如骨髓和淋巴系統。許多生活方式要素都會增加血癌的風險，包括吸煙、不良飲食、缺乏運動和飲酒過多。這些惡性會影響血球的生長和運作。由於人口變化、生活方式決定、環境暴露、遺傳傾向和診斷方法改進等要素，這一領域正在不斷擴大。

輸血部門預計在預測期內年複合成長率最高

預計輸血領域在預測期內年複合成長率最高。輸血透過補充血球數量來增加血液中血紅素的含量。輸血可以提高身體為重要器官和組織提供氧氣的能力。呼吸急促、虛弱和疲勞是可以透過輸血緩解的一些症狀。此外，輸血對於維持接受積極治療（例如血液惡性化療）的患者至關重要。對於患有嚴重血液缺陷的人來說，輸血可以緩解不適，提高生活品質，過著更積極的生活，並減輕症狀。

比最大的地區

由於患者群體意識的提高，預計北美在預測期內將佔據最大的市場佔有率。醫學研究和開發處於北美前沿。這包括配合措施發現新藥、增強現有治療方法和探索新想法。輝瑞（美國）和 Medexus 製藥公司（加拿大）等主要公司正在向該地區擴張。血液疾病的高發生率、先進的醫療保健系統和蓬勃發展的製藥部門是推動北美血液疾病市場的一些原因。

複合年複合成長率最高的地區：

預計亞太地區在預測期內年複合成長率最高。亞太地區人口多樣化，具有不同的遺傳傾向和環境因素，導致多種血液疾病。印度和東南亞國家等某些國家的地中海貧血和鐮狀細胞性貧血等遺傳性血液疾病的發生率很高。日本和國外的製藥公司正積極致力於血液疾病治療方法、藥物和藥物的開發和普及。此外，主要企業和新興製藥公司和研究機構之間的頻繁進步和合作正在推動該地區血液疾病市場的擴張。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球血液疾病市場：依類型

  • A型血友病
  • B型血友病
  • 血管性血友病
  • 其他類型

第6章 全球血液疾病市場：依疾病分類

  • 遺傳性血液疾病
  • 血紅素紊亂
  • 骨髓增生性疾病
  • 血小板相關疾病
  • 血癌
  • 血漿病
  • 其他疾病

第7章 全球血液疾病市場：依治療類型

  • 藥物治療
    • 血漿衍生凝血因子濃縮物
    • 重組凝血因子濃縮物
    • 去氨加壓素
    • 抗纖溶藥
    • 纖維蛋白密封劑
  • 因子替代療法
  • 荷爾蒙替代療法
  • 輸血
  • 管道分析

第8章 全球血液疾病市場：按配銷通路

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章 全球血液疾病市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Novo Nordisk A/S
  • Bayer AG
  • Sanofi
  • Octapharma AG
  • Pfizer Inc.
  • Grifols International SA
  • Medexus Pharma, Inc.
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • Baxter International Inc.
  • Takeda Pharmaceutical Company Limited
  • Thea Laboratories
  • Zydus Group
  • Wellona Pharma
  • Ferring Pharmaceuticals
  • Novartis AG
  • OASIS Medical
  • Bausch & Lomb Incorporated
  • Johnson & Johnson Services Inc.
  • Sun Pharmaceutical Industries Limited
Product Code: SMRC23933

According to Stratistics MRC, the Global Blood Disorders Market is accounted for $15.08 billion in 2023 and is expected to reach $26.73 billion by 2030 growing at a CAGR of 8.6% during the forecast period. Blood disorders are a group of medical conditions that affect the blood and its components. They are also known as hematologic disorders or haematological conditions. Some blood disorders are genetic and present from birth, while others can develop later in life due to various factors such as infections, autoimmune conditions, or exposure to certain toxins. Treatment options can range from medication and lifestyle changes to more intensive therapies.

According to the World Federation of Hemophilia Report, in the year 2017, worldwide around 315,423 people are affected by blood disorders. Among them approximately 196,706 people are living with Hemophilia, 76,144 people with von Willebrand disease (VWD) and 42,573 with other blood disorders.

Market Dynamics:

Driver:

Increasing clinical trials and R&D

Significant improvements in the diagnosis and management of blood diseases have been made as a result of the growing emphasis on clinical trials, research, and development. The development of more accurate and sensitive blood condition diagnostic tests is the result of research efforts. These tests enable quicker and more precise identification, allowing medical professionals to start treating patients earlier. The market expansion is being fuelled by the rising investment in clinical trials, research, and development for blood diseases, which is significantly improving patient outcomes.

Restraint:

Lack of standardized guidelines

The complexity and variability of blood diseases, the paucity of research on some subtypes, and the requirement for individualised treatment strategies are a few causes for the absence of standardised recommendations. It is frequently necessary for haematologists, oncologists, geneticists, and other healthcare experts to work together to treat blood diseases. Treatment strategies could alter as a result of coordinating care among these various experts. Along with this, the market's expansion is hampered by resource constraints and a lack of data on rare conditions.

Opportunity:

Rising awareness regarding blood disorders

As part of larger initiatives to improve healthcare systems and address health inequalities internationally, the increased knowledge of blood disorders in developing countries is an important step towards improving the health and well-being of those afflicted by these ailments. Increased awareness draws greater funding and attention to efforts to investigate and find treatments for blood illnesses. As a result, increased funding for research and development has driven awareness initiatives, which is boosting market demand.

Threat:

Inadequate reimbursement policies

Treatments for blood disorders include prohibitively costly, cutting-edge procedures like gene therapy and stem cell transplants. A multidisciplinary approach is frequently used to treat blood diseases, including input from haematologists, oncologists, geneticists, and other experts. In addition, factors including the limited market size, the complexity of the treatment plans, and the lack of competition cause government and commercial insurers to have constrained budgets, which may lead to reduced reimbursement rates. This issues are impeding the market demand.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the blood disorders market. The pandemic has led to delays in routine medical appointments and diagnostic testing, which has led to delayed diagnoses and treatment of blood disorders. The pandemic has caused delays and shortages in the distribution of vital medications for blood disorders by upsetting the world's pharmaceutical and medical device supply chains.

The blood cancers segment is expected to be the largest during the forecast period

The blood cancers segment is estimated to have a lucrative growth. Blood cancers originate in the blood-forming tissues of the body, such as the bone marrow or lymphatic system. Blood cancer risk is enhanced by a number of lifestyle factors, including smoking, eating poorly, being inactive, and drinking too much alcohol. The growth and operation of blood cells are both impacted by these malignancies. The segment is expanding as a result of factors such as demographic shifts, lifestyle decisions, environmental exposures, genetic predispositions, and improvements in diagnostic methods.

The blood transfusions segment is expected to have the highest CAGR during the forecast period

The blood transfusions segment is anticipated to witness the highest CAGR growth during the forecast period. Blood transfusions increase the amount of haemoglobin in the blood by replenishing the blood cell count. The body's capacity to oxygenate essential organs and tissues is improved by transfusions. Shortness of breath, weakness, and fatigue are some of the symptoms that are lessened by doing this. Additionally, blood transfusions are essential in sustaining patients receiving aggressive therapies like chemotherapy for blood malignancies. For people with severe blood flaws, it can ease their discomfort and enhance their quality of life, enabling them to lead more active lives and have fewer symptoms.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the increasing awareness among the patient population. Research and development in biomedicine are at the forefront in North America. This involves initiatives to find novel medicines, enhance current therapies, and investigate fresh ideas. Major firms like Pfizer Inc. (U.S.) and Medexus Pharma, Inc. (Canada) are present in this region. The high frequency of blood diseases, an advanced healthcare system, and a thriving pharmaceutical sector are some of the reasons that are driving the market for blood disorders in North America.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The APAC region is home to a diverse population with varying genetic predispositions and environmental factors, leading to a wide range of blood disorders. Certain countries like India and some Southeast Asian nations, have higher incidences of genetic blood disorders like thalassemia and sickle cell anaemia. Pharmaceutical firms from both domestic and foreign markets are actively involved in the creation and dissemination of treatments, therapies, and drugs for blood diseases. Additionally, frequent advancements and partnerships between key players, as well as emerging pharmaceutical firms and research institutes, are fueling the Blood Disorders Market expansion in this region.

Key players in the market:

Some of the key players profiled in the Blood Disorders Market include: Novo Nordisk A/S, Bayer AG, Sanofi, Octapharma AG, Pfizer Inc., Grifols International SA, Medexus Pharma, Inc., CSL Limited, F. Hoffmann-La Roche Ltd., Baxter International Inc., Takeda Pharmaceutical Company Limited, Thea Laboratories, Zydus Group, Wellona Pharma, Ferring Pharmaceuticals, Novartis AG, OASIS Medical, Bausch & Lomb Incorporated, Johnson & Johnson Services Inc. and Sun Pharmaceutical Industries Limited.

Key Developments:

In October 2023, Sanofi announced that it has entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extra intestinal pathogenic E. coli (9-valent) developed by Janssen, currently in Phase 3.

In February 2023, A Johnson & Johnson drug for rare infant blood disorder achieves main goal of phase 2 test. The drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses.

Types Covered:

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Other Types

Disorders Covered:

  • Genetic Haematology Disorders
  • Haemoglobin Disorders
  • Myeloproliferative Disorders
  • Platelet Based Disorders
  • Blood Cancers
  • Plasma Disorders
  • Other Disorders

Treatment Types Covered:

  • Drug Therapy
  • Factor Replacement Therapy
  • Hormone Replacement Therapy
  • Blood Transfusions
  • Pipeline Analysis

Distribution Channels Covered:

  • Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Blood Disorders Market, By Type

  • 5.1 Introduction
  • 5.2 Hemophilia A
  • 5.3 Hemophilia B
  • 5.4 Von Willebrand Disease
  • 5.5 Other Types

6 Global Blood Disorders Market, By Disorder

  • 6.1 Introduction
  • 6.2 Genetic Haematology Disorders
  • 6.3 Haemoglobin Disorders
  • 6.4 Myeloproliferative Disorders
  • 6.5 Platelet Based Disorders
  • 6.6 Blood Cancers
  • 6.7 Plasma Disorders
  • 6.8 Other Disorders

7 Global Blood Disorders Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Drug Therapy
    • 7.2.1 Plasma-derived Coagulation Factor Concentrates
    • 7.2.2 Recombinant Coagulation Factor Concentrates
    • 7.2.3 Desmopressin
    • 7.2.4 Antifibrinolytics
    • 7.2.5 Fibrin sealants
  • 7.3 Factor Replacement Therapy
  • 7.4 Hormone Replacement Therapy
  • 7.5 Blood Transfusions
  • 7.6 Pipeline Analysis

8 Global Blood Disorders Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Drug Stores
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Retail Pharmacies

9 Global Blood Disorders Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novo Nordisk A/S
  • 11.2 Bayer AG
  • 11.3 Sanofi
  • 11.4 Octapharma AG
  • 11.5 Pfizer Inc.
  • 11.6 Grifols International SA
  • 11.7 Medexus Pharma, Inc.
  • 11.8 CSL Limited
  • 11.9 F. Hoffmann-La Roche Ltd.
  • 11.10 Baxter International Inc.
  • 11.11 Takeda Pharmaceutical Company Limited
  • 11.12 Thea Laboratories
  • 11.13 Zydus Group
  • 11.14 Wellona Pharma
  • 11.15 Ferring Pharmaceuticals
  • 11.16 Novartis AG
  • 11.17 OASIS Medical
  • 11.18 Bausch & Lomb Incorporated
  • 11.19 Johnson & Johnson Services Inc.
  • 11.20 Sun Pharmaceutical Industries Limited

List of Tables

  • Table 1 Global Blood Disorders Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Blood Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Blood Disorders Market Outlook, By Hemophilia A (2021-2030) ($MN)
  • Table 4 Global Blood Disorders Market Outlook, By Hemophilia B (2021-2030) ($MN)
  • Table 5 Global Blood Disorders Market Outlook, By Von Willebrand Disease (2021-2030) ($MN)
  • Table 6 Global Blood Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Blood Disorders Market Outlook, By Disorder (2021-2030) ($MN)
  • Table 8 Global Blood Disorders Market Outlook, By Genetic Haematology Disorders (2021-2030) ($MN)
  • Table 9 Global Blood Disorders Market Outlook, By Haemoglobin Disorders (2021-2030) ($MN)
  • Table 10 Global Blood Disorders Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 11 Global Blood Disorders Market Outlook, By Platelet Based Disorders (2021-2030) ($MN)
  • Table 12 Global Blood Disorders Market Outlook, By Blood Cancers (2021-2030) ($MN)
  • Table 13 Global Blood Disorders Market Outlook, By Plasma Disorders (2021-2030) ($MN)
  • Table 14 Global Blood Disorders Market Outlook, By Other Disorders (2021-2030) ($MN)
  • Table 15 Global Blood Disorders Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 16 Global Blood Disorders Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 17 Global Blood Disorders Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2021-2030) ($MN)
  • Table 18 Global Blood Disorders Market Outlook, By Recombinant Coagulation Factor Concentrates (2021-2030) ($MN)
  • Table 19 Global Blood Disorders Market Outlook, By Desmopressin (2021-2030) ($MN)
  • Table 20 Global Blood Disorders Market Outlook, By Antifibrinolytics (2021-2030) ($MN)
  • Table 21 Global Blood Disorders Market Outlook, By Fibrin sealants (2021-2030) ($MN)
  • Table 22 Global Blood Disorders Market Outlook, By Factor Replacement Therapy (2021-2030) ($MN)
  • Table 23 Global Blood Disorders Market Outlook, By Hormone Replacement Therapy (2021-2030) ($MN)
  • Table 24 Global Blood Disorders Market Outlook, By Blood Transfusions (2021-2030) ($MN)
  • Table 25 Global Blood Disorders Market Outlook, By Pipeline Analysis (2021-2030) ($MN)
  • Table 26 Global Blood Disorders Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 27 Global Blood Disorders Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 28 Global Blood Disorders Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 29 Global Blood Disorders Market Outlook, By Online Pharmacies (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.